Zavondemstat

CAS No. 1851412-93-5

Zavondemstat( —— )

Catalog No. M36329 CAS No. 1851412-93-5

Zavondemstat (QC8222 free base) is a histone lysine demethylase 4 (KDM4) inhibitor with anticancer and antitumor activity for the study of triple-negative and breast cancers.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 231 Get Quote
5MG 359 Get Quote
10MG 588 Get Quote
25MG 1132 Get Quote
50MG 1822 Get Quote
100MG 2250 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Zavondemstat
  • Note
    Research use only, not for human use.
  • Brief Description
    Zavondemstat (QC8222 free base) is a histone lysine demethylase 4 (KDM4) inhibitor with anticancer and antitumor activity for the study of triple-negative and breast cancers.
  • Description
    Zavondemstat (QC8222; TACH 101) is an inhibitor of histone lysine demethylase 4D (KDM4D) with antineoplastic activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Histone Demethylase
  • Recptor
    Histone Demethylase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1851412-93-5
  • Formula Weight
    431.53
  • Molecular Formula
    C26H29N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(NC=1C(C(O)=O)=CC=NC1)[C@H]2C=3C(=CC(N(C)C4=CC=C(C(C)C)C=C4)=CC3)OCC2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. WHO Drug Information-World Health Organization (WHO).
molnova catalog
related products
  • Zavondemstat

    Zavondemstat (QC8222 free base) is a histone lysine demethylase 4 (KDM4) inhibitor with anticancer and antitumor activity for the study of triple-negative and breast cancers.

  • P3FI-63

    P3FI-63 is a selective KDM3B inhibitor (IC50: 7 μM) with antitumor activity for the study of fusion-positive rhabdomyosarcoma and other transcriptionally addictive cancers.

  • MRTX-1719

    MRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC 50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells.